16 completed, 4 recruiting, 1 active not recruiting, 1 unknown. 7 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Fibrous Dysplasia, Polyostotic: new trials by email Literature Review of Fibrous Dysplasia, Polyostotic trials Research Report on Fibrous Dysplasia, Polyostotic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study Visit 1 at the center - Fibrous Dysplasia of Bone, McCune Albright Syndrome | Not applicable | Completed | University Hospital, Clermont-Ferrand | 39 | 2026-04-08 | 2026-08-21 |
| Assessment of Femoral Failure Load and Fracture Risk in Rare Bone Disorders Using MEKANOS Tool. Case Study of Fibrous Dysplasia of Bone/McCune Albright Syndrome Application of MEKANOS tool to CT scans - Fibrous Dysplasia/McCune-Albright Syndrome | Active not recruiting | Hospices Civils de Lyon | 20 | 2025-03-10 | 2026-04-02 | |
| Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions. - Fibrous Dysplasia of Bone | Unknown | Hospices Civils de Lyon | 545 | 2024-01-19 | 2024-02-29 | |
| DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) Denosumab 120 Mg/1.7 Ml Inj, Placebo - Fibrous Dysplasia, McCune Albright Syndrome | Phase 4 | Recruiting | Natasha Appelman-Dijkstra | 82 | 2023-06-13 | 2025-01-29 |
| Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia Burosumab - Fibrous Dysplasia Of Bone | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 12 | 2022-12-07 | 2026-02-02 |
| Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia denosumab - Fibrous Dysplasia | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 15 | 2022-10-12 | 2026-01-20 |
| Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data Fibrous Dysplasia, Fibrous Dysplasia of Bone | Recruiting | Istituto Ortopedico Rizzoli | 200 | 2022-05-12 | 2026-05-12 | |
| Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities blood sample - Fibrous Dysplasia, Albright Syndrome | Completed | Hospices Civils de Lyon | 33 | 2021-03-10 | 2023-03-24 | |
| Pain in Fibrous Dysplasia MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT - Fibrous Dysplasia/McCune-Albright Syndrome | Not applicable | Completed | Boston Children's Hospital | 37 | 2021-01-05 | 2026-10-27 |
| Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test - McCune-Albright Syndrome, Fibrous Dysplasia | Withdrawn | Yale University | 2018-08-07 | 2019-09-04 | ||
| Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry Fibrous Dysplasia, McCune Albright Syndrome | Recruiting | Tovah Burstein | 600 | 2016-10-31 | 2025-08-12 | |
| TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE Tocilizumab, Placebo - Fibrous Dysplasia of Bone | Phase 2 | Completed | Hospices Civils de Lyon | 19 | 2013-05-05 | 2025-10-02 |
| Faslodex in McCune-Albright Syndrome Fulvestrant - Puberty, Precocious, McCune-Albright Syndrome | Phase 2 | Completed | AstraZeneca | 30 | 2006-01-31 | 2024-03-05 |
| Histamine Responsiveness in McCune-Albright Syndrome McCune-Albright Syndrome | Completed | Children's Mercy Hospital Kansas City | 22 | 2004-08-01 | 2018-02-06 | |
| Arimidex in McCune Albright Syndrome Arimidex 1 mg - McCune-Albright Syndrome | Phase 2 | Completed | AstraZeneca | 40 | 2002-08-01 | 2015-09-01 |
| A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Pegvisomant - McCune Albright Syndrome, Polyostotic Fibrous Dysplasia | Phase 3 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 10 | 2001-06-01 | 2008-03-04 |
| Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome Letrozole - McCune Albright Syndrome, Polyostotic Fibrous Dysplasia | Phase 1 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 25 | 2000-08-03 | 2017-07-02 |
| Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Polyostotic Fibrous Dysplasia | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 50 | 1998-12-15 | 2017-07-02 | |
| Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome McCune-Albright Syndrome | Recruiting | National Institute of Dental and Craniofacial Research (NIDCR) | 500 | 1998-12-13 | 2026-10-30 | |
| Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Fosamax (Alendronate) - Polyostotic Fibrous Dysplasia | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 40 | 1998-08-24 | 2017-07-02 |
Showing 20 of 23. Sign in to see all of them.
Fibrous Dysplasia of Bone (17) · Puberty, Precocious (3) · Bone Diseases (2) · Pain (2) · Acromegaly (1) · Adenoma (1) · Bone Diseases, Metabolic (1) · Calcinosis (1) · Dermatomyositis (1) · Diabetes Mellitus (1) · Hyperparathyroidism (1) · Hyperplasia (1) · Hypoparathyroidism (1) · Osteomalacia (1)
Bone Diseases, Developmental (23) · Musculoskeletal Diseases (23) · Osteochondrodysplasias (23) · Bone Diseases (21) · Endocrine System Diseases (7) · Fibrous Dysplasia of Bone (6) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Calcium Metabolism Disorders (3) · Gonadal Disorders (3) · Neoplasms (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Pathologic Processes (2)
Denosumab (2) · Alendronate (1) · Anastrozole (1) · Blood Specimen Collection (1) · Fulvestrant (1) · Glucose Tolerance Test (1) · Letrozole (1) · Mass Screening (1) · Testolactone (1) · burosumab (1) · pegvisomant (1) · tocilizumab (1)
National Institute of Dental and Craniofacial Research (NIDCR) (8) · Hospices Civils de Lyon (5) · AstraZeneca (2) · Boston Children's Hospital (1) · Children's Mercy Hospital Kansas City (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Istituto Ortopedico Rizzoli (1) · Natasha Appelman-Dijkstra (1) · Tovah Burstein (1) · University Hospital, Clermont-Ferrand (1) · Yale University (1)
United States (14) · France (8) · Italy (3) · Germany (2) · United Kingdom (2) · Netherlands (1) · Russia (1)
Alison M Boyce, M.D. (3) · Angela L Turpin, MD (1) · Cemre Robinson, MD (1) · Natasha Appelman-Dijsktra, MD, PhD (1)
PMID 10535539, PMID 12119276, PMID 17229001, PMID 20157193, PMID 22640754, PMID 22999294, PMID 25033066, PMID 30124968, PMID 30496606, PMID 31035847, PMID 31196103, PMID 32644197, PMID 35104665, PMID 37804088, PMID 39710366
2005 (1)